Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Keith Chau
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters; questions recorded in 6).
- Questions
- 7on tracked calls
- Challenge rate
- 0%none of 7 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 6with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 1 company
AMCRAmcor7 questions · 6 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
Would you agree that $2.5 billion is a reasonable number to target for the next 12 months?
Show response
Steve agreed the ~$2.5 billion combines the natural cash flow of the business (EBITDA minus CapEx, interest and taxes) plus the $500 million Middle East recovery, consistent with the pathway to 3x leverage by the end of 2027 alongside continued mid-single-digit EBITDA growth.
Calendar 2026 Q1
are you expecting to see that step up? And given the higher working capital at the moment and the investment in working capital, should we see an over recovery of cash in calendar year '27
Show response
Steve confirmed cash recovery likely as supply chains normalize in calendar 2026-2027, though timing depends on supply chain stabilization. Stub period leverage not expected above fiscal year-end. Real deleveraging improvement expected in calendar/fiscal 2027 from synergy capture, EBITDA growth, and divestiture proceeds.
Calendar 2025 Q4
I just wanna go back to the comment around recently renegotiated customer contracts
Show response
PK explained two angles: (1) better volume visibility and commitments from customers in low-volume beverage environment, and (2) inflation recovery adjustments in existing contracts. No cost to achieve. Both provide improved line of sight and better pricing going forward.
Calendar 2025 Q2
what gives you a degree of confidence that there is a line of sight to improving business performance
Show response
PK separated strategic assessment from short-term operations. Stabilization expected over a couple of quarters before exploring market alternatives. Customer considerations are paramount. Emphasized discipline on timing and value creation across all 11 non-core businesses.
Calendar 2025 Q1
how many suppliers have responded to that email or letter?
Show response
PK declined to discuss specifics of supplier negotiations, citing sensitivity. Acknowledged the question but said conversations will be handled respectfully with their playbook. Would not provide detail on supplier response rates.
Calendar 2024 Q4
underlying consumer demand still being fairly tepid and seemingly in the second quarter, that hasn't changed too much
Show response
PK confirmed consumer modestly softer in Q2 but overall volume performance still positive at fourth consecutive quarter of improvement. Healthcare destocking largely over, which will improve mix in H2. No structured restocking expected.
the midpoint does imply a slightly greater skew to the second half
Show response
Michael explained phasing aligned with historical average of 55-58% in H2. Q4 typically delivers 30%+ of full-year EPS with strong operating leverage. Healthcare mix improvement and volume growth support confidence.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| AMCR Amcor | 7 | 0%none of 7 questions |
- AMCRAmcor · 7 questions0%none of 7 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 1 |
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | No questions recorded | — | — |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q3No questions recorded
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Capital Allocation3
- Margin2
- Demand2
- Cost Pressure1
- M&A1
- Inventory1
- Guidance Reliability1